• argenx reported its Phase 3 ALKIVIA trial of efgartigimod met primary and key secondary endpoints in the combined autoimmune myositis population.
• Immune-mediated necrotizing myopathy (IMNM) patients showed significant, sustained improvement versus placebo, supporting a potential first treatment for the condition.
• A US filing for IMNM is planned by the end of 2026, supported by FDA Breakthrough Therapy Designation.
• Dermatomyositis patients showed clinically meaningful improvement, but results did not reach statistical significance in this smaller group.
• Results will be presented at ACR Convergence on November 11, 2026, from 9:15-9:30 a.m. ET.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. arGEN-X SE published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611071001PRIMZONEFULLFEED1001302375) on November 07, 2026, and is solely responsible for the information contained therein.